Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phototoxicity Potential of Bemotrizinol (6%)
NCT05254925Phase 2Completed
- Sponsor
- DSM-Firmenich
- Start
- Feb 2022
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bemcentinib in sunburn (4 arms), sponsored by DSM-Firmenich. Primary endpoint: Determination of the Photoxicity potential of 6% Bemotrizinol. Started Feb 2022; status: completed.
02
Drugs
bemcentinib
03
Conditions
sunburn
Beyond the preview
Go deeper on NCT05254925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05254925.